Cargando…
HMGB1 and thrombin mediate the blood-brain barrier dysfunction acting as biomarkers of neuroinflammation and progression to neurodegeneration in Alzheimer’s disease
BACKGROUND: The blood-brain barrier (BBB) dysfunction represents an early feature of Alzheimer’s disease (AD) that precedes the hallmarks of amyloid beta (amyloid β) plaque deposition and neuronal neurofibrillary tangle (NFT) formation. A damaged BBB correlates directly with neuroinflammation involv...
Autores principales: | Festoff, Barry W., Sajja, Ravi K., van Dreden, Patrick, Cucullo, Luca |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4995775/ https://www.ncbi.nlm.nih.gov/pubmed/27553758 http://dx.doi.org/10.1186/s12974-016-0670-z |
Ejemplares similares
-
Proximate Mediators of Microvascular Dysfunction at the Blood-Brain Barrier: Neuroinflammatory Pathways to Neurodegeneration
por: Festoff, Barry W., et al.
Publicado: (2017) -
Altered Nrf2 Signaling Mediates Hypoglycemia-Induced Blood–Brain Barrier Endothelial Dysfunction In Vitro
por: Sajja, Ravi K., et al.
Publicado: (2015) -
In vitro characterization of odorranalectin for peptide-based drug delivery across the blood–brain barrier
por: Sajja, Ravi K., et al.
Publicado: (2019) -
Thrombin and the Coag-Inflammatory Nexus in Neurotrauma, ALS, and Other Neurodegenerative Disorders
por: Festoff, Barry W., et al.
Publicado: (2019) -
Impact of altered glycaemia on blood-brain barrier endothelium: an in vitro study using the hCMEC/D3 cell line
por: Sajja, Ravi K, et al.
Publicado: (2014)